Company Overview and News

PSBank looks to raise P8 billion via stock rights offer in Q1 2019

2018-10-16 bworldonline
PHILIPPINE SAVINGS Bank (PSBank) is set to raise approximately P8 billion through a stock rights offer (SRO) next quarter to support its growth.

Peso rises to one-month high

2018-10-16 bworldonline
THE PESO strengthened to a one-month high on Tuesday as the dollar weakened due to lower-than-expected US retail data and negative sentiment at Wall Street.

AC Energy inks $83-million EPC contract for development of solar farms in Vietnam

2018-10-14 bworldonline
AC ENERGY, Inc., along with its Vietnamese partner, has signed construction and financing contracts for the development of solar plants in Vietnam valued at an estimated $83 million, the Ayala-led company said during the weekend.

RCBC partners with KB Kookmin Bank

2018-10-08 bworldonline
RIZAL Commercial Banking Corp. (RCBC) has partnered with KB Kookmin Bank Korea, which will provide banking services and financial information assistance to Korean and Philippine firms.
RZLLY 8545 8543 RCB

Inflation hits fresh 9-year high in Sept

2018-10-05 bworldonline
INFLATION surged anew in September to a fresh nine-year high as the strong typhoon which hit last month worsened supply issues for rice and other crops, spurring calls for further interest rate hikes from the central bank.

August factory output growth slows

2018-10-05 bworldonline
MANUFACTURING output continued to expand in August albeit at a slower pace compared to a month earlier, the Philippine Statistics Authority (PSA) reported last Friday.

Metrobank raises P8.68 billion

2018-10-04 bworldonline
METROPOLITAN Bank & Trust Co. (Metrobank) has raised P8.68 billion from the first tranche of its P25-billion long-term negotiable certificates of deposit (LTNCD) program meant to diversify its funding sources.

World’s worst stock mart still not cheap enough to buy

2018-10-03 bworldonline
AS the Philippine Stock Exchange Index (PSEi) dipped below 7,100 during Tuesday’s session, taking its valuation to its lowest level since January 2016, Metropolitan Bank & Trust Co. is among the firms that’s staying on the sidelines.

PHL regains ASEAN factory lead

2018-10-01 bworldonline
IMPROVEMENT of Philippine manufacturing activity remained “modest” in September, according to a monthly survey IHS Markit conducted for Nikkei, Inc., but “robust” domestic consumption, a “solid” rise in new orders and “upbeat business confidence” offset muted foreign demand and “strong” inflation to propel the country back to fore among major economies of the Association of Southeast Asian Nations (ASEAN).

Yields on gov’t debt surge on inflation expectations

2018-09-30 bworldonline
YIELDS ON government securities surged amid expectations of faster inflation towards yearend after the central bank tightened monetary policy rates by 50 basis points (bp) last Thursday.

NEDA sees ‘net’ positive impact of trade war

2018-09-19 bworldonline
THE PHILIPPINE ECONOMY could end up with a net gain in the trade war between the US and China as the world’s biggest economy seeks other sources of cheaper goods, the National Economic and Development Authority (NEDA) said late Tuesday.

Metrobank offers LTNCDs

2018-09-17 bworldonline
METROPOLITAN BANK & Trust Co. (Metrobank) started offering long-term negotiable certificates of time deposit (LTNCD) on Monday to diversify its funding sources.

Trade gap widens on import surge

2018-09-11 bworldonline
FLAT merchandise export sales and inbound foreign goods’ continued surge caused the country’s trade gap to widen further in July, the Philippine Statistics Authority (PSA) reported on Tuesday, putting more pressure on the peso that has lately been hitting its weakest level in nearly 13 years (Read article here).

RCBC offers first tranche of P20-B LTNCD program

2018-09-10 bworldonline
RIZAL COMMERCIAL Banking Corp. (RCBC) has started its offer the first tranche of its P20-billion long-term negotiable certificates of deposit (LTNCD) program to raise funds.

Approved building permits rise 11.7% in Q2 — PSA

2018-09-06 bworldonline
CONSTRUCTION starts, based on approved building permits, grew 11.7% year-on-year, driven by non-residential projects, the Philippine Statistics Authority (PSA) said.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 76970D107